Demodox blepharitis treatment shows positive results, says Tarsus

Publication
Article
Optometry Times JournalJuly digital edition 2020
Volume 12
Issue 07

IRVINE— Tarsus Pharmaceuticals announces positive results of its Phase 2a Mars Study and the release of the results of a Phase 2b randomized controlled study.

The Mars study demonstrated that the use of TP-03 for 4 weeks was well-tolerated and showed promising efficacy in the treatment of demodex blepharitis with treatment effects persisting for at least 90 days, according to the company.

“My colleagues and I are excited that there is a possible new therapy that targets the underlying cause of disease for nearly half of all blepharitis patients,” says Dr. Roberto Gonzalez-Salinas, MD, PhD, the principal investigator for the study conducted at the Asociación para Evitar la Ceguera in Mexico City.

Study design

Mars was a single-arm, open-label study that evaluated the safety and efficacy of TP-03 in 15 participants with demodex blepharitis. The prespecified efficacy endpoints were improvement in collarette score and mite density. Participants dosed one drop of TP-03 in each eye bid for 28 days.

Results showed statistically significant decreases in mean collarette score and mite density beginning at Day 14 and continuing throughout the study period of 90 days with no adverse events reported, according to the company.

Related: NIH launches clinical trials network: COVID-19 vaccine underway

Specific results were:

• Collarette score: The mean grade showed statistically significant improvement from baseline to Day 14 and had a 2-grade improvement overall on a 4-point scale by the end of the treatment period at Day 28.

• Mite eradication: The average mites/lash showed statistically significant improvement from baseline to Day 14 and had a 10-fold improvement from baseline by the end of the treatment period at Day 28.

• Safety: No treatment-related adverse events were reported and there were no clinically significant changes in visual acuity, intraocular pressure and slit-lamp biomicroscopy findings including in corneal staining.

Says Tarsus CEO Bobak Azamian, MD, PhD: “These results are the beginning of a strong, consistent data set we are generating with TP-03 to treat the underlying cause of demodex blepharitis and other conditions.”

Looking ahead

Tarsus planned to release results of the Jupiter Study, a Phase 2b Randomized Controlled Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis, at the American Optometric Association’s (AOA) annual meeting, this year held virtually.

In addition, the company plans to file an IND for TP-03 to treat demodex blepharitis and begin a Phase 3 trial later this year. Its clinical pipeline also includes studies in meibomian gland disease (MGD) and rosacea.

Related: Ptosis therapy gets first-in-category FDA nod

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Eva Kim, MD, shares visual outcomes of EVO implantable collamer lens in patients with low to moderate myopia
Drs Brianna Rhue and Diana Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.
Dr Ashley Wallace Tucker speaks on the Myopia Management Navigator.
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Arkansas Optometric Association legislative cochairs Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD, discuss their involvement in their bill and provide context for its relevance.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
© 2025 MJH Life Sciences

All rights reserved.